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ABSTRACT  
  
With new trends in drug development and testing, it must be determined 
whether the current state of balance of ethos (the moral norm) and regula (the 
legal framework) can successfully protect patients while keeping the door to 
scientific innovation open. The rise of the Clinician Investigator (CI) in both 
academic and private research introduces a challenge to the protection of subjects 
in the conflicting dual role of physician and scientist. Despite the constant 
evolution of regulation and ethical standards, questions about the roles‘ combined 
effectiveness in relation to this challenge persist. Carl Elliot describes the suicide 
of a patient-subject enrolled in an industry-funded physician-run anti-psychotic 
pharmaceutical drug trial in a 2010 Mother Jones article. Elliot provides a 
personal account of discrepancies seen in the ethical principles of beneficence, 
respect for subjects and justice. Through analysis of the problems presented in the 
case as a model for potential dangers in clinical research, the effectiveness of 
ethics and law in protecting human subjects is examined. While the lag between 
ethical standard and regulation has historically shown to cause similar issues, the 
misconception of current regulation and ethical standards may be contributing to 
the decrease in subject protections. After IRB approval of subject protections in 
the research protocol, CIs have been shown to downgrade their responsibility to 
maintaining ethos through the course of the trial. And, despite their experience in 
patient-centered ethos as a physician, CIs may be inclined to substitute these 
values for the ethos of a researcher, with the goal to avoid therapeutic 
misconception. Maintaining personal responsibility for subjects beyond regulatory 
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structure, and promoting the welfare of the subjects in regards to the ethical 
standard of research investigators, will provide added security for subjects and 
decrease opportunity for exploitation in future research. 
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Chapter 1 
INTRODUCTION 
 There is a complex relationship between medicine and scientific research. 
In our health-driven society, one cannot exist without the other. Declines in 
physical and mental well-being cry out for biomedical solutions. In response, 
research is conducted by both academic institutions and private firms to develop 
therapies and to determine the success of these innovations. This circle continues 
as research uncovers more information about the human function and its reaction 
to internal and external stressors. Maintaining a balance between medical practice 
and research is crucial in continuing the pursuit for better health outcomes and the 
well-being of society. If health is declining at a pace much quicker than the 
development of therapies, individuals will not have access to the proper 
biomedical interventions and, as a result, will fall victim to a broad range of 
health conditions. To keep up, researchers must strive to pinpoint the origin of 
diseases and conditions leading to declines in health and understand their 
functioning in order to start the search for a therapeutic intervention.  
 A similar relationship exists between ethics and the law. Morals and social 
values create a shared sense of what is good and what falls short. Consensus on 
these principles helps to create a framework on which the society can exist and, 
hopefully, thrive. As new members are added to society, this structure can provide 
guidance to morals and values that are able to be adopted. However, a cyclic 
pattern does not always exist between the ethics and law. A consensus on value 
does not always result in the formation of legal structure. And, on the other hand, 
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the existence of a regulation may not reflect the consensus of morality in the 
society. So, despite of the connection existing between ethics and law, the two 
may appear as separate bodies of structure and this has potential for discrepancy 
between the goals and outcomes of each. Wavering in the relationship of ethics 
and law has the potential to create conflict when developing structure amongst 
other cyclic relationships, such as that of scientific research and medical practice.  
 The purpose of this study is to better understand the ethics and regulation 
surrounding clinical research in the constantly evolving medical field. With the 
addition of new challenges in drug development and research, it must be 
determined whether the current state of balance of ethics and law can successfully 
protect patients while keeping the door to scientific innovation open. The 
challenge presented in this case focuses on physicians acting as research 
investigators. These ‗clinician investigators‘ have to balance the conflicting duties 
as a physician and a scientist in order to pursue involvement in clinical research. 
Although layers of regulation have been added to protect human subjects in 
response to challenges in research over the years, a potential for gaps in 
protections continue exist and can lead to the unnecessary harm of the 
participants. It needs to be determined whether the combination of value systems 
and the current regulatory system, for both physicians and researchers, is capable 
of supporting the protection of human subjects in clinical research. If not, 
discussion of the duality of the clinician-investigator role may shed light on how 
to proceed with clinical research of this nature. 
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1. The Rise of the Clinician Investigator 
 Two distinct roles have been established in clinical medicine: the scientist 
and the clinician. On one hand, scientific investigators work at the front end using 
past knowledge and experimentation to advance their field. They work to expand 
the boundaries of science, particularly medical science, from the lab bench. Their 
goals tend to focus more on knowledge expansion than on health of individuals 
enrolled of their research. On the other hand, clinicians apply the science through 
the work of diagnosis and treatment. Their focus has been on therapeutic 
beneficence toward individual patients. Their work toward advancing health has 
created a caring, humanitarian persona, but may not appear to understand the 
scientific under-workings of their career. Although these roles appear distinct, 
they are dependent on each other for successful health outcomes. Scientific 
knowledge is necessary to create new diagnosis and treatment techniques and the 
physician-patient relationship is necessary to apply these techniques to increase 
the health of patients. Therefore, the separation of these roles may not be the most 
efficient in creating new health knowledge and better health outcomes.  
 Recently, the joining of the roles of physician and scientific investigator has 
been encouraged as a means to advance progress in both the scientific and 
medical communities. The goal is to develop a person who can both advance 
science while improving the health of individuals. This ‗knight in shining armor‘ 
of sorts is the Clinician Investigator (CI). A CI is a physician who also acts as a 
scientific investigator through producing scientific research and conducting 
clinical trials in their field of practice while still treating patients (Lader et al. 
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2004). This person can go back and forth between the bench and the bedside and 
can foster basic research into clinical settings of practice. Also, he or she can take 
clinical research and make it more relevant to applied clinical trials. Although the 
CI may seem to connect these previously distinct roles effectively and efficiently, 
there exists a concern in attempting to balance the traditional goals of the 
physician and the scientific investigator (Miller, Rosenstein, and DeRenzo 1998; 
Gorski, 2009). The culmination of trying to advance science while ensuring 
therapeutic benefit creates an ethical challenge, and potentially a conflict of 
interest, for the CI. 
 
2. From Academic Medical Centers to Private-Sector Research 
 Research universities classically have been associated with CI research. The 
academic setting provides physicians with the support needed to conduct 
extensive clinical trials. Also, the presence of science departments alongside 
medical centers allows for streamlined transfer of information. The US and 
Canada have made attempts to fund more CI‘s through the development of 
MD/PhD programs, which make medical training programs more flexible with 
scientific exploration (Goldstein and Brown, 1997; Morin et al., 2002; Culotta, 
1993). These programs allow medical candidates to become exposed to research 
methods in the academic setting, which creates a starting place for CI pursuits. 
Also, all medical research is developed and executed under the regulation and 
approval processes of trusted university IRBs. This setting creates an ideal for the 
conduct of CI research. 
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 To manage the financial burden of research with the goal of maintaining 
steady profits, pharmaceutical companies are developing new strategies for cost-
efficient research. Recently, there has been outreach by corporate research 
sponsors toward private-sector physicians to pursue academic research in their 
clinical setting (Morin, Rakatansky, Riddick, et al. 2002). Specifically, the use of 
private-sector research was shown to increase by three times previous spending in 
the 1990s and is still on the rise (Cockburn, 2004). The physicians provide 
expertise and interest in the field, as well as pools of potential research subjects 
(Klein and Fleischman, 2002). This arrangement has the potential to be 
financially beneficial for both the pharmaceutical company and the contracted 
physician. The physician can gain access to additional salary while the 
pharmaceutical company can hope for success in research and development of 
new drugs to cope with recent patent expiration.  
 Motivations for involvement in research, as a private-sector physician, go 
beyond financial compensation. There is a general consensus that research is 
inherently good for all involved because it assists in the expansion of scientific 
knowledge (Klein and Fleischman, 2002; Lader, 2004; Snyder and Meuller, 2008; 
Boyd, Cho and Bero, 2003). The expansion of knowledge can lead to the 
fulfillment of the individual physician‘s academic goals, which may not 
commonly be available in the setting of private practice (Klein and Fleischman, 
2002). These academic goals may include not only the completion of research, but 
the ability to publish work and get academic credit for their participation (Lader, 
2004). When becoming involved in research, the physician may have the 
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opportunity to receive more education about the drug through discussion with 
those involved in pre-clinical development of the therapy. This education could 
include participation in scientific sessions to learn more about the issue at hand or 
to present results after the course of the trial (Lader, 2004). Also, the opportunity 
to take part in research trials could add to the prestige of the practice or institution 
participating in research (Lader, 2004). The physician would be able to associate 
his/her practice of medicine with the cutting edge medical technologies currently 
in development, which could lead to positive reviews and potential increase in 
patients. Finally, by participating in research, physicians have the opportunity to 
improve the health of their current patients. Through the use of the most state of 
the art pharmaceuticals and devices, they would be able to provide the best health 
care, the primary objective of medical practice (Snyder and Mueller, 2008). 
 
3. Discrepancy in Conduct 
 Primary care physicians enrolling patients in clinical trials causes a new set 
of ethical concerns, which vary from clinical research ethics and physician-patient 
conduct alone. And, unlike the academic CI, the private practice physician may 
not have clinical research training or experience. Although physicians undertaking 
research and caring for patients may both conduct their craft for the overarching 
goal of harm avoidance, the motivations are different (Brody and Miller 2003). 
Research, unlike clinical medicine, does not include a duty to promote therapeutic 
benefit and, thus, the blurring of these career paths has the opportunity to cause 
miscommunication with patients in their role as research participants, as well as 
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internal moral struggles for the CI. While facing these challenges, it must be 
determined whether the attempts to balance these two roles as one individual is 
the most ethical and efficient way of advancing science (Bloom 2003). 
 Steps have been taken to evaluate the role of the CI in the both the academic 
and private practice setting. This duality creates ethical concern, both for the 
patients enrolled in the study and the physician acting as investigator, and this is 
expressed throughout the literature. However, with sufficient focus on informing 
the physician of the research properly and informing the participants of not only 
the trial but also the special role the physician has assumed, participants can be 
protected and significant progress in research can be made (Klein and Fleischman, 
2002). With multiple credible sources releasing proposed action in moving 
forward with research, progress toward making changes to include proper 
protection would seem expected.  
 However, in a 2008 study, Fisher described that physicians contracted for 
private (for-profit) research do not feel personally responsible for the protection 
of their subjects (2008). The trial protocol, designed by the pharmaceutical 
company, includes informed consent component to be discussed with the 
enrolling participants. Information includes the purpose of the trial, the process of 
the trial, the risks and benefits from the therapy, and other pertinent information 
(Rogers and Schwartz, 2002). This component, along with the protocol as a 
whole, is reviewed by an Institutional Review Board prior the beginning of any 
human subjects research. The IRB, a private company hired by the 
pharmaceutical company in this case, determines whether the risks have been 
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minimized and benefits appear to outweigh risk involved, along with other 
features for protecting participants while advancing science. Since this process is 
reviewed by the drug‘s developers as well as a committee whose job is to protect 
patients, some physician-investigators feel that all unwarranted risks have been 
accounted for and the trial has been deemed ethical and can be carried out without 
further analysis (Fisher, 2008). A discrepancy exists between the role physicians 
play in the ethics of the trial and their perception of participant protection. It is 
possible that progress in protection of subjects in for-profit CI research through 
legislation is not being made despite the in-depth conversations occurring in the 
ethics community. 
 
4. Research Question 
The remainder of the thesis is directed toward answering the following question: 
Given duality between research and clinical care, how do we balance ethos and 
regula to lead to good outcomes for participant/patients?  
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Chapter 2 
ETHOS AND REGULA: ETHICS AND LAW 
 
1. Definitions 
  Ethos is one of Aristotle‘s three modes of persuasion. Ethos refers to the 
character of the speaker, whose intent is to portray credibility through fair-
mindedness (Aristotle, 1991 in Constantines, 2001). To appear credible, one must 
express practical wisdom, virtue and good will. Although ethos is a term of 
rhetoric, it has been adapted to social norms of modern science and be used as a 
tool to foster discourse (Constantines, 2001). The arena of science creates a 
unique environment for the development of ethos. Robert Merton has categorized 
scientific reasonableness into four norms: universalism, communality, 
disinterestedness, and organized skepticism, (Merton, 1989 in Constantines, 
2001). Bernard Barber added a fifth norm, ethical neutrality (Barber, 1952 in 
Wunderlich, 1974). These norms work as platforms for developing perceptions of 
ethos. Merton explains, ―[the] ethos of science is that affectively toned complex 
of values and norms which is held to be binding on the man of science. The norms 
are expressed in the forms of prescriptions, proscriptions, preferences, and 
permissions. They are legitimatized in terms of institutional values... [The ethos 
of science] can be inferred from the moral consensus of scientists...‖ (Merton, 
1989 in Constantines, 2001). Ethos today is expressed in the form of ethics codes 
and recommendations of institutions and nations, as well as in mutual discourse 
between professionals and scholars. These norms work to serve the well-being of 
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the community and the individual to the community‘s standard of the morality. 
Continued discourse on ethics help to better shape these norms as science 
progresses. 
 Although the ethos may be seen as a standard in a society, regula, Latin for 
‗rule‘, dictates legal obligations (Du Plessis, 2010). Changes in regula, also 
referred to as regulations and laws, are determined by the governing body. Regula 
often encompasses the moral standards of the society. However, all regula does 
not necessarily reflect these judgments and may even conflict with the ethos. In 
science, the regulations governing research and treatment have worked to 
incorporate the discussion of ethics, but discrepancies have been present over the 
course of its history. 
 
2. Ethos and Regula in Human Subjects Research 
 Human subject research has been practiced as medicine has evolved. But, it 
was not until revelations about the treatment of subjects after the end of the 
second World War that catalyzed ethical discussion of its practice. With news of 
exploitation released through journalism, the necessity for change in research 
conduct was obvious (Rothman, 1987). The Nuremberg Code was established in 
1949 as a response to the Nazi War Crimes Trials involving abuses through 
human experimentation. This code encouraged that consent by all human subjects 
research should be voluntary, hoping to avoid cases of exploitation as witnessed 
in World War II. Also, it expressed that participants should be free to discontinue 
taking part in a trial at any point. In addition, the concepts of determining a 
   11 
favorable risk-benefit ratio and justifying the potential risks were introduced to 
the discussion of research ethics. 
 The World Medical Association released the Declaration of Helsinki, an 
international guideline for human subjects research ethics based on the 
Nuremberg Code, in 1964. This code took the principles given in Nuremberg and 
correlated them to the standard duties of physicians, creating relevance for 
research in pursuit of research with therapeutic objectives. Since its release, it has 
been noted as the most significant document in the development of human 
subjects research regulation (Rothman, 1987). It has been revised six times since 
its release, the most recent being in 2008. Helsinki became the overwhelming 
standard among practitioners, creating a universal baseline for ethics discussion 
and a foundation for later regulation. The Declaration of Helsinki was based on 
the fundamental principle of respect for the participant. This respect created a 
need for informed decision-making regarding enrollment. Also, it set precedence 
for protection of the subject from harm over opportunity for scientific gain.  
 Driving the provisions were ongoing instances of human exploitation and 
unfavorable risk-benefit ratios. Prominent in the release of this information was 
Henry Beecher, a research professor at Harvard Medical School. In a seminar 
article published in The New England Journal of Medicine, he presented twenty-
two examples of misconduct in human subjects research spanning various 
disciplines of medicine (Beecher, 1966). This information not only surprised 
readers, but also showed that exploitation in research was happening despite the 
introduction of ethical codes to promote participant protection. The impact of this 
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information eventually resulted in the development of more detailed structures for 
informed consent as well as the formation of institutional review boards (IRB) to 
oversee research of this nature (Rothman, 1987). But Beecher, by contrast, was 
especially concerned to reinforce the ethos of medicine as a core element of 
conscientious research. 
 The public awareness of flaws in human subjects research was at an all-time 
high with the exposé of the Tuskegee Syphilis Trials. In this experiment, black 
men of low socioeconomic classes with syphilis were left untreated in order to 
learn about the course of the disease. At the time of the trial, a standard 
medication was available and approved for the treatment of syphilis (Heller, 1972; 
Jones, 1981). A national panel was appointed to review this case and it was 
determined that current standards for research ethics were inadequate. The risk of 
this experiment is obvious, and the Tuskegee syphilis experiment is widely 
interpreted as blatantly exploiting members of vulnerable socioeconomic classes 
and racial groups. The lack of participant protection through subjecting 
participants to avoidable harm while exploiting their racial and socioeconomic 
backgrounds proved that change needed to continuously be made among 
regulation of human subject research. Since Tuskegee came to public attention, 
the treatment of human subjects participating in biomedical research has been 
regulated and overseen federally and through individual institutions with the 
additional of supplementary codes. An evolving modern standard understanding 
of clinical research ethics has provided grounding to evaluating the dynamic 
nature of biomedical research under the framework of clinical research ethics. 
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3. Current Regula 
i. 45 CFR Part 46, Department of Health and Human Services, 1991 
 This regulation is the primary set of Federal human subjects research 
protection regulation in the United States, adopted in 1991. Also referred to as the 
Common Rule, this legal code applies to federally funded human subjects 
research and sets forth the legal standards and requirements for the conduct of 
covered human subjects. All research subject to the Common Rule is required to 
follow specific guidelines for obtaining independent review by an institutional 
review board and informed consent for subjects. The research undertaken with 
government funding must comply with the Common Rule‘s requirements. 
 All human subjects research is to be reviewed by an Institutional Review 
Board (IRB). The specifics of IRB constitution are stipulated by the Common 
Rule; an IRB must have a minimum of 5 members representing a diversity of 
expertise, including members affiliated with and members independent of the 
institution in which the protocol under review will be undertaken. The purpose of 
the IRB is to review proposed human subjects research to protect the safety and 
interests of the human subjects. IRB approval relies on the requirements that the 
project minimizes risk to subjects, the potential risks are reasonable in the scope 
of anticipated benefit, the selection of subjects is justified, and informed consent 
is both substantial and properly documented. Approval can be granted with or 
without revisions or the project can be rejected. All research approved by IRBs is 
subject to ongoing oversight by officials of the institution at any time. 
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 Specific requirements are signifiers of the ethical requirements of informed 
consent. The baseline elements are as follows: explanation of the research, 
expected duration of participation, description of the protocol, identification of 
experimental portions of protocol, potential risks to individual, anticipated benefit 
of trial to individual and/or society, list of alternative procedures available, 
statements concerning confidentiality, compensation for injury, and available 
procedures for case of injury, contact information for further questions and in case 
of injury, statement of voluntariness of participation, and statement of ability to 
withdraw. The following elements may be necessary for inclusion based on the 
research at hand: potential for unforeseeable harms, cause for termination of the 
subject‘s participation by the investigator, additional costs of participation, 
consequences of withdrawal from study, disclosure of new information as study 
progresses, and the size of the study. Waiver or alteration of informed consent 
requirements may be granted by the IRB when research includes the following: 
potential for no more than minimal risk, information that can affect welfare of 
subject, and when informed consent would disturb the validity of a study. 
Documentation of informed consent must be signed by the subject or legal proxy 
on the IRB-approved form, with a copy made for the subject. In cases of oral 
presentation of informed consent, a shorter version of the document is to be 
signed by participants and a witness of the oral presentation. Signatures may be 
waived in cases of potential for confidentiality breach or when research presents 
no more than minimal risk, which is similar to standard medical procedure. 
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ii. FDA Regulation 
 The Food and Drug Administration continuously is updating their 
regulations to reflect Congress‘s laws pertaining to the products the FDA 
regulates (FDA, 2012). The organization translates the laws through drafting 
proposals, which are scrutinized internally and by the public before becoming 
enacted. This process creates an opportunity for feedback and improvement on the 
policies of the FDA. The resulting regulation is applied to all FDA sanctioned 
research and is filed under the Code of Federal Regulations Title 21 (Food and 
Drugs), Chapter 1 (Food and Drug Administration). Clinical research legislation 
includes the responsibility of IRBs and the details of informed consent procedure. 
 All research is to be reviewed by an IRB prior to conducting the clinical 
portion of the trial and throughout its course (21 CFR 56.103, 2011). As in 45 
CFR Part 46, the IRB must consist of at least 5 members, of both science and 
non-science backgrounds. Creating a diverse group of individuals, intellectually 
and based on other personal characteristics, works to promote the welfare and 
protection of the diverse population of subjects participating in the research (21 
CFR 56.107, 2011). Each IRB must register with the FDA prior to participating in 
regulatory duties (21 CFR 106, 2011). These duties, as stated in 21 CFR Part 
56.109.a, are to ―review and have authority to approve, require modifications in 
(to secure approval), or disapprove all research activities...‖ (2011). Evaluation of 
the research includes review of any risks to the subject, the reasonably of said 
risks to anticipated benefits, and fair subject selection (protection of vulnerable 
groups) (21 CFR 56.111, 2011). The IRB is to continuously monitor the study in 
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order to maximize safety and confidentiality of the subjects, where applicable. 
This approval also requires that subjects be provided with sufficient informed 
consent prior to participation, with the only exceptions being minimal risk, 
procedures that do not require consent outside realm of research, and sanctioned 
emergencies (21 CFR 56.109.c, 2011). All approval can be suspended or 
terminated secondary to, but not limited to, cases of unexpected serious harm to 
research subjects (21 CFR 56.113, 2011). 
 Informed consent is expanded upon in 21 CFR Part 50, which addresses the 
protection of human subjects (2011). The process of informed consent is to 
provide the subject with substantial information to make a decision of whether or 
not to participate while minimizing instances of coercion and outside influence 
(21 CFR 50.20, 2011). This document prohibits waiving the legal rights of the 
participant as well as the legal responsibility of the investigator and related 
parties. The ‗basic elements‘ of the informed consent are as follows: (a) statement 
of the project, procedure, and that research is experimental, by nature, (b) 
foreseeable risks, (c) reasonably expected benefits, (d) alternative treatment 
available, (e) statement of confidentiality, and (f) availability medical care 
provided in instances of harm. It may also include, among other items, one or 
more of the following: (a) statement of unforeseeable risks, (b) potential 
termination on behalf of the investigator, and (c) consequences from terminating 
trial prior to completion (21 CFR 50.25, 2011). A physical manifestation of these 
elements is to be signed by the subject or his or her legal proxy, with copies kept 
by both the subject and the investigator (21 CFR 50.27, 2011). 
   17 
  
4. Current Ethos 
i. Moral Norms for Practitioners 
a. The Hippocratic Oath 
  The Oath of Hippocrates is a Greek text recorded 400 BCE that continues 
to be sworn, in some form, by physicians professing to practice medicine ethically 
(North (trans.), 2002). It is commonly seen as a rite of passage for those students 
becoming practitioners. Its original text professes that one shall swear by the oath 
in the practice and teaching of medicine. It expresses need for patient protection 
by the physician, stating that one shall ―do no harm or injustice to them.‖ (North 
(trans.), 2002) The translation also states that the physicians shall practice 
―regimens which will benefit [their] patients according to [their] greatest ability 
and judgment‖ (2002). These statements affirm both beneficence and non-
maleficence in the practice of medicine. 
 Although it is still used it in some form today, the original text does not 
encompass all aspects of today‘s medicine. Modern derivations, which have 
removed portions of the original and added portions regarded as more relevant, 
are also recited and referenced when addressing medical ethics (Antiel et al., 
2011). A widely used 1964 version addresses beneficence and non-maleficence in 
practice similar to that of the original text. It also addresses modern ideas of 
patient care. Bedside manner is included as follows, ―I will remember that there is 
art to medicine as well as science, and that warmth, sympathy, and understanding 
may outweigh the surgeon's knife or the chemist's drug‖ (Lasagna, 1964). It 
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creates a sense of humanity in the practice of a science. The humanity of the 
patient is also mentioned, noting, ―... I do not treat a fever chart, a cancerous 
growth, but a sick human being‖ (Lasagna, 1964). Through the eyes of this 
humanity, physicians will face decisions of life and death, which this modern 
version suggests should be handled with thoughtful personal judgment. 
 
b. American Medical Association – Medical Ethics 
 The American Medical Association‘s (AMA) Code of Medical Ethics 
provides physicians with a standard for upstanding behavior in the medical 
profession. This code serves to illuminate the ongoing responsibilities physicians 
have toward their patients, society, members of the field, and their own self 
(AMA, 2001). The AMA set forth a series of nine principles to act as a core of 
ethics in medical practice. Although these principles are not legally binding, the 
AMA holds that ―ethical obligations typically exceed legal duties‖ (AMA 1.02, 
2001) – in other words, ethos exceeds regula. Acting within the law does not 
ensure ethical judgment and practice. Thus, physicians must ensure that justice is 
upheld as dictated by ethics, even when current regulation may conflict. And, 
despite the lack of legal bearing, failure to follow specific duties and obligations 
set out in this code or instances of unethical conduct may result in disciplinary 
action, such as suspension or expulsion from the profession (AMA 1.01, 2001). 
The physician‘s responsibilities as cited in the principles are as follows: (a) to 
provide competent care with compassion and respect, (b) to be honest and 
maintain professionalism to current standards, (c) to act lawfully and to promote 
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legal change where needed, (d) to respect patients, colleagues, other professionals 
in the field and their privacy, (e) to continue to study, advance scientific 
knowledge and to call on knowledge of other professionals when needed, (f) to 
have freedom to choose who to serve, who to work with, and where to work (in 
non-emergency cases), (g) to participate in the betterment of community health, 
(h) maintain responsibility to patient as forefront in all practices, and (i) provide 
health care access to all people (AMA, 2001). 
 A physician-patient relationship arises when a physician works to meet the 
medical needs of a patient. By AMA opinion, this relationship is based on mutual 
trust and creates an ethical obligation the physician has toward the patient (AMA 
10.015, 2001). This obligation is to place the patient‘s welfare above all else 
during the course of the relationship, including above institutional and physician 
self-interest. This is achieved through using sound judgment to make medical 
decisions while upholding the interests of the individual patient. These interests 
are protected through providing patients with a right to making health care 
decisions independently based on knowledge of the procedure, with guidance 
from the physician, and in confidence to maintain privacy. Beyond respect and 
dignity, the patient also has the right to timely attention to and care of his or her 
health, based on the needs presented. The physician must preserve these 
obligations until the patient no longer is in medical need, the patient discontinues 
the relationship, or the physician coordinates continued care elsewhere. The 
physician may not discontinue care if treatment is still medically necessary for the 
health of the patient (AMA 10.01, 2001).  
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 The patient is also a key part to successful physician-patient relationships 
and must take an active role in the betterment of their own health (AMA 10.02, 
2001). While the physician has duties to provide care, the patient has the 
responsibility to open communication through the decision-making process and 
treatment course. This includes scenarios in which the patient wishes to revisit 
medical decisions and reconsider their options. The patient also has the 
responsibility to comply with the treatment course. These are based on the 
patient‘s right to make autonomous decisions, asserting self control in their 
medical care. In line with informed consent, the patient or their proxy always 
have the right to refuse medical care. 
 
c. American Psychological Association Ethics 
 Beyond medicine, ethic standards are established for psychological therapy 
by the American Psychological Association. The standard of ethics for treatment, 
as well as research, is based upon a series of five general principles. The 
principles are in place to guide and encourage psychologists to practice to their 
professional best, in terms of ethics (APA, 2010). They are not obligatory in 
nature, but act as inspiration for success in day to day work.  
 Beneficence and non-maleficence is the first of the five principles. 
Psychologists should work to benefit their patients while taking the precaution to 
avoid harms. The protection of their patient‘s welfare is a direct result of decision 
making on the part of the psychologist, so this decision making should be made 
independent of outside influence. Personal influence, such as mental and physical 
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health factors, should also assessed, as it can also affect the welfare of those 
treated (APA, 2010). 
 Fidelity and responsibility make up the second principle. Psychologists 
have both scientific and professional responsibilities to those they work with. All 
conflicts of interest and opportunities for exploitation are to be managed. It is 
their obligation to uphold these standards and maintain trust within the 
relationships established (APA, 2010). 
 The third general principle is integrity. As stated in the APA‘s Ethical 
Principles of Psychologists and Code of Conduct, ―Psychologists seek to promote 
accuracy, honesty and truthfulness in the science, teaching and practice of 
psychology.‖ (APA, 2010) They are to not engage in activities that would 
compromise the health of their patients or the accuracy of research. In cases 
where deception is ethically justifiable, it is the responsibility of the psychologists 
to understand consequences and mistrust that may evolve and correct these 
problems to the best of their ability (APA, 2010). 
 Justice is the fourth of the general principles. All persons are entitled to 
access to and benefit from the progress of the field. Psychologists must promote 
this through managing biases in practice and research and understanding 
limitations, both personally and of the field (APA, 2010). 
 Wrapping up the five principles is respect for people‘s rights and dignity. 
―Psychologists respect the dignity and worth of all people, and the rights of 
individuals to privacy, confidentiality, and self-determination‖ (APA, 2010). 
Special considerations should be taken into account to ensure autonomy for 
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varying levels of vulnerability. They must take into account their patient‘s culture 
and individual characteristics, such as age and gender, and work to eliminate any 
bias stemming from these factors. Prejudice is not condoned (APA, 2010). 
 In terms of therapy, psychologists must obtain informed consent for the 
course of treatment. This process should include information regarding the 
treatment, risks involved, alternative course of therapy, any fees in place, and the 
involvement of third parties, if relevant. Also, the limits of confidentiality 
between the psychologist and patient are to be explicitly defined. Sufficient time 
to ask questions or state concerns is to be given to the patient or third party prior 
to beginning therapy (APA, 2010). 
 Ethical consideration also applies to the termination of therapy. The 
psychologists can terminate the therapy if it is shown that the patient is no longer 
in need of the service, no longer is benefiting from it, or if harm is probable if the 
therapy is continued. Psychologists can also terminate therapy when they feel 
endangered or threatened by the patient or a person related to the patient. Prior to 
termination, psychologists are to provide proper counseling explaining the end of 
therapy and alternative services or providers, if necessary (APA, 2010).  
 
ii. Moral Norms for Researchers 
a. The Belmont Report, the National Commission for the Protection of Human 
Subjects in Biomedical and Behavior Research, 1979 
 In response to the investigation of the Tuskegee syphilis experiment, the 
US government needed to determine the core principles of human subjects 
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research ethics and to create a way in which these principles could be executed 
and protected. The National Commission for the Protection of Human Subjects in 
Biomedical and Behavior Research was ordered in 1974 via the National 
Research Act to complete this task (NIH, 1979). By 1979, the commission had 
created and published the Belmont Report, a document highlighting research ethic 
standards and recommended implementation. Although this document does is not 




The first section of this document differentiates the ―boundaries between practice 
and research‖ (1979), defining and distinguish the variance in the goals of 
research and practice. Medical practice involves actions to enhance the well-being 
of the individual and has expectation of successful therapeutic benefit. Medical 
research involves actions to test a hypothesis with a rigid protocol to expand upon 
current knowledge of the field, without expectation of therapeutic benefit of the 
subject. Straying from medical standards of practice does not always constitute 
experimentation. Practice of innovative techniques can be handled on an 
individual basis. However, in more extreme cases of innovation, a formal 
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Section II 
 The second section of the Belmont Report set forth three basic ethical 
principles to support and structure all succeeding regulation of human subjects 
research. Justification of all human subjects research should be based upon: 
respect for persons, beneficence, and justice.  
 Respect for persons recognizes that humans are autonomous beings and 
should be treated as such. Autonomous persons are capable of rational and 
reasonable thought and their interest in self-determination should not be 
compromised when participating in clinical trials. In cases that autonomy is 
diminished, individuals should be protected from exploitation. Based on varying 
levels of maturity and rational capability, protection should be awarded 
appropriately. These cases should be assessed individually based upon the 
potentials for risk and benefit prior to proceeding. 
 Beneficence ensures well-being is protected during the process of clinical 
research. Two rules have been formulated to address beneficence. The first is that 
potential harms to subjects should be minimized. The second is that the study‘s 
expected benefits should exceed the potential harms. This principle marries the 
ethos of the Hippocratic Oath with the field of research. In addressing risks and 
benefits, the research can be better defined and the goal is more likely understood 
by participants and the public. 
 Finally, justice defines how the burden of participation and distribution of 
knowledge must be equalized in order to justify research with human subjects. As 
seen in previous cases of misconduct in research, such as the Tuskegee Syphilis 
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Trials, the risk often falls of populations of low social classes while high classes 
reap the benefits of the treatments developed. Justice can be balance based on 
need, effort, societal contribution, merit, and other qualities. The choice should 
exercise fairness and stay consistent for minimized chance for exploitation. 
 
Section III 
 The third and final section of the report states how the three 
aforementioned principles should be applied to current regulation. Three 
conditions are highlighted: informed consent, risk/benefit analysis, and participant 
selection. 
 Informed consent aims to respect the autonomy of all patients by allowing 
them to determine whether to participate in the study. Information about the trial 
is provided to the individual, informing them of not only the protocol, but 
research goals, any risk involved in participating and alternatives to participating. 
Patients also are to be informed that they can withdraw from the trial at any time. 
Any information pertinent to the trial should be disclosed at all times, allowing 
the participant to get truthful information as well as truthful answers to questions 
asked. Patients should also be properly debriefed, providing any available 
research results. Informed consent also hinges upon the participant‘s 
comprehension of the information provided. Comprehension helps to protect the 
autonomy of the patients. In cases of increased risk, ensuring comprehension 
becomes more important and testing the absorbance of information could be 
helpful. Based on the information given and processed by the patient, 
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voluntariness in participation is the final piece in protecting the autonomy of the 
patient. The informed consent process should be executed in a way that does not 
coerce the participant to enroll. Offers of unfit reward or the exaggeration of 
benefit is not permitted. The influence of others involved in decision-making, 
such as relatives, should be monitored as well to protect the participant. 
 Assessing the risks and benefits of the trial provides information for IRBs 
about whether the research can be justified and beneficence be maintained. The 
term ‗risk‘ refers to the probability for harm caused by the trial. The range of 
harm can differ and should be weighted based on the expected severity. The term 
‗benefit‘ refers to the anticipated welfare resulting from the trial. Benefit from the 
trial can occur at both the individual and societal levels. Justification of research 
is possible when risk and benefit is systematically balanced or, preferably, 
weighted toward benefit. Also, justification should reflect that humans are never 
inhumanely treated, humans are necessary for the success of the trial, chance for 
significant risk is justified by potential benefit, vulnerable populations are 
protected and involved when possible, and all discussion of risk and benefit 
presented for IRB approval is clearly stated in the informed consent procedure. 
 Justice in clinical trials is exercised in the selection of research subjects at 
both the individual and societal level. Individuals as well as societal groups 
should not be cherry-picked based on favorability or increased ability to exploit. 
This can help to decrease a burden to participate upon an improper individual or 
an unfit group. However, the selection of a specific population can be justified if 
proving to balance risk and benefit, such as choosing adults over children. 
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Investigators should be aware of any bias (social, cultural, racial, etc.) that may 
arise during a trial, intentional or not, for biases may skew results in dramatic but 
also in subtle ways. Institutionalized and other vulnerable populations should not 
be targeted as sources of participant pools. The decreased capacity to consent 
based on their surroundings, mental status, and basic needs can easily be 
influenced and create a potential for exploitation. 
 
b. American Medical Association – Research Ethics for Clinicians 
 Increasing numbers of physicians, both academic and non-academic, are 
becoming involved in partnerships with biotechnology and pharmaceutical 
industry to further research with clinical trials (AMA 8.0315, 2001). The AMA 
has set out recommendations to assist physicians in maintaining their professional 
ethical responsibility when they take part in clinical investigations (AMA 2.07, 
2001). As noted in chapter 1, there is a duality of purpose in clinical investigation 
– the research is designed to advance knowledge but tends to be undertaken with 
patients under clinical care. The AMA recognizes this duality. The clinical 
investigation is to serve the purpose of producing scientifically valid and 
significant knowledge within the standards of research. But, despite the presence 
of the trial, the patient should be given the same attention to their welfare, safety, 
and well-being as in physician-patient relationships.  
 In cases of using clinical investigations primarily for treatment, all 
judgment must be made in the best interest of the patient, as exists in the 
physician-patient relationship. The patient should voluntarily agree to use an 
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experimental drug as course of treatment and informed consent process that 
explicitly states any risks and potential benefits (AMA 2.07, 2001). The physician 
is required to answer any questions of the patient and provide alternative therapy 
to the trial. Coercion and exaggeration of clinical benefit should not be used to 
influence trial enrollment. 
 Physicians should also be aware of the inherent conflict between the roles 
of physician and scientific investigator and any additional conflicts of interests. 
To manage them properly, the AMA recommends that physicians should only 
participate in trials under their scope of practice (AMA 8.0315, 2001). 
Additionally, physicians should receive training in responsible research conduct 
and scrutinize the investigation for subject welfare provisions and scientifically 
sound protocol prior to agreeing to participate. In cases where patients are 
subjects, and vice versa, physicians should work to illuminate the differences in 
responsibility of physician and investigator to the patient. It may be appropriate to 
have someone other than the physician to obtain consent to any clinical 
investigations. The physician should make sure protocols contain provisions for 
medical care for participants in the case of complications and should make 
participants aware of any financial interests the physician has in the research. 
Finally, the physician should ensure that all data collected be released 
unobstructed and abnormally delayed by the institution or company they are 
contracted to.  
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c. Current Discussion of Research Ethics 
 The ethical standard for the treatment of human subjects in clinical research 
extends beyond what is governed by ethical codes and regulation. As seen in the 
Belmont Report, ethical principles have served as a starting place for the 
development of both ethical standards and regulation. Informed consent has 
primarily been thought of as a way to make human subjects research ethical 
(Emmanuel et al., 2000). But, regulation in this manner does not always 
incorporate new evolving standards, which are actively discussed by ethicists, 
physicians, scientists and other academics. Additional principles have been 
offered to be added to the current requirements for research approval. 
 The completion of the research should have social, scientific, or clinical 
value (Vanderpool, 1996 in Emmanuel et al., 2000). Value, in the case of 
therapeutics, can be referenced to various goals. Value can be found in 
improvement in health and well-being, the gathering of information that could 
lead to discovery of therapeutic interventions, and an increase in the knowledge of 
biological systems (Levine, 1988 in Emmanuel et al., 2000). Research that may 
take many years may still be justified if goals are reasonable and probable. 
Projects have opportunity to unnecessarily repeat a previously completed trial or 
produce results that cannot reasonably be translated into medical practice. It is 
important to identify value in the research prior to conducting the study because 
resources necessary for completion are finite and pursuing research with little or 
no value opens the door for exploitation of participants (Vanderpool, 1996 in 
Emmanuel et al., 2000).  
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 The protocol of clinical research should be scientifically valid. Social, 
scientific, and clinical value can be compromised when errors exist in the 
structure of the project at hand and results are not reliable (Rutstein, 1970 in 
Emmanuel et al., 2000). Investigators should use their academic background as 
well as exercise care when developing their protocol to avoid these mistakes 
(Resnik, 1998). In the comparison of existent therapies, clinical equipoise must be 
present (Freedman, 1987). Controversy to whether the new treatment is predicted 
to be more successful than the current treatment needs to exist. Research is not 
justified if a consensus already exists on the better therapy. Once a scientifically 
valid research question and protocol exists, changes can be made to the methods 
to ensure the most ethically favorable participant experience (Emmanuel et al., 
2000). Again, this principle can be justified by finite resources and controlling 
exploitation. 
 Honesty and openness should be exercised between the investigator and the 
participant enrolled in the study (Resnik, 1998). The investigator should be sure to 
give informed consent with all relevant information, including that of risk and 
potential harm. Also, the investigator should be open and honest about any 
financial conflict of interest that may exist in the research project. Allowing the 
participant access to the information will strengthen the respect for the subject as 
well as allowing them to make the most autonomous decision about their 
enrollment and participation. Failure to disclose information about the protocol 
itself, the goals of the project or any reward driving enrollment can lead to 
exploitation. 




 As the landscape of clinical research continues to change, it is important to 
recognize the existing challenges and then determine how they are impacting 
current cases. The following case falls in the intersection of the for-profit 
pharmaceutical industry and the rise of the clinician investigator. Carl Elliott 
interprets a personal account of a case of suicide during an individual‘s 
enrollment in an industry-funded physician-run anti-psychotic pharmaceutical 
drug trial in his Mother Jones article (2010). With examples of potential 
discrepancy in subject protection evidence, but no official findings of wrongful 
activity, this case presentation provides an interesting platform for evaluating the 
functionality of ethics in current regulation. This is so even though it is a singular 
example. And, through analyzing elements of this interpretation on clinical trials, 
it can reveal sources of lapse in participant protection when physicians assume the 
role as research investigator and, consequentially, stray away from their norms of 
care in medical practice. 
 Note: The following study will be summarized as interpreted by Carl 
Elliott. Although the study pertains to a real case, the information is presented 
as a personal matter. Therefore, all information from this case will be 
analyzed on a hypothetical basis and all discussion will reflect potential for 
discrepancy in participant protection as inspired by the case, not a critical 
discussion of the case itself. 
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 A first-episode schizophrenic participant was enrolled in the trial while 
under medical supervision of Dr Stephen C. Olsen, University of Minnesota 
Academic Health Centers (UM-AHC). This 26 year old patient had a known 
history of homicidal tendencies and was noted to be at risk to harm others. 
Minnesota statute holds that patients who are psychotic and dangerous can be 
treated without consent due to mental instability or incapability for the course of 
14 days. At this time, the patient must comply with the treatment and follow-up 
instructions by their physician. This either can be done involuntarily through 
admission to a treatment facility or on an extended-outpatient basis with strict 
guidelines. The patient opted for this ―stay of commitment‖. Instead of 
prescription treatment, the patient was enrolled in a research study. After two 
weeks of treatment within the confines of the hospital, the patient was placed in a 
halfway house. 
 The research study was comparing three FDA-approved ―atypical‖ anti-
psychotic drugs, Seroquel, Xyprexa, and Risperdal (the medication originally 
used to treat the patient after arriving at the health center). This study was 
comparing the effectiveness of these drugs in first episodes of schizophrenia and 
was sponsored by AstraZeneca, the manufacturer of Seroquel, under the 
supervision of the UM-AHC. This trial targeted participants with homicidal risk 
and no history of suicidal risk. The study did not allow participants to change 
drugs if their double-blinded assignment was not working properly. Patients were 
also not allowed to take additional anti-psychotic drugs during the course of the 
trial. The patient was followed up regularly throughout the study by a social 
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worker and occasionally (3 times in this case) was evaluated by one of the 
physician-investigators. 
 Despite the patient‘s mother‘s account of attempts to warn the 
investigators about the patient‘s lack of progress in the trial, the patient remained 
in the study. From perspective of the mother, the worsening condition of the 
patient was overlooked by the investigators, thus making the attempts to remove 
the patient from the trial unsuccessful. Approximately 4.5 months after starting 
the trial, the patient committed suicide and was found dead in his residence. 
 When the results of the trial were published, Seroquel was shown to be 
comparatively effective to Risperdal and Zyprexa. The study noted that two 
suicides occurred during the course of the trial, and both of the patients were on 
Seroquel. They stated that these cases were closely followed by their investigators 
during the course of the study. When the study was shown to other experts in the 
field, initial concern was shown for the statistical significance of the results. The 
study measured the effectiveness of the study by the lack of discontinuation of the 
study. All patients who finished their course of the drug were shown to have 
effective treatment, despite their condition and its change (or lack of change) 
during the trial. Experts also think that the study lacks dimension by not including 
the classic anti-psychotic drugs. Most importantly, concern stems from the 
thought that the study appears to be market-driven instead of focusing on the 
advancement of medicine and science. 
 The case presentation raises a number of ethical concerns, to which I now 
turn. 
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1. Capacity to Consent 
i. Concern 
 As stated in the article, when this case was brought to the attention of legal 
authorities, it was stated that consent was appropriately given because all 
participants were of similar mental statuses and gave consent (Elliott, 2010). This 
is particularly troubling because state statute governs that patients who are 
psychotic and dangerous are incapable of making decisions about their health for 
at least 14 days after onset of the condition. Since the subject in this case was 
admitted for treatment under this guideline, he displayed a need for intervention 
and has the potential for continued states of psychosis beyond the period of 
institutionalization based on his medical history. With the ordering of continued 
treatment, the physicians do express concern for the health of the patient, 
suggesting that his mental status is still in jeopardy beyond this 14 day mark. 
 As outlined in the Declaration of Helsinki, vigilance must be exercised 
when enrolling vulnerable groups in human subject research (Article 8) (2008). 
The presence of an unstable mental status may affect the individual‘s ability to 
exercise autonomy. Not only may the individual not understand the trial itself, 
they may not have the capacity for decision-making regarding their own well-
being. This document then states that in the case of mentally incapable, along 
with incompetent and physically incapable individuals, surrogate consent is to be 
given (Article 23-24). Although it is recommended for assent of the individual 
along with the consenting decision of the proxy, the inclusion of a rationally 
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capable surrogate, who is concerned for the well-being of the individual enrolling 
in the trial, decreases the opportunity for exploitation.  
 Informed consent has been seen as the cornerstone of research ethics. 
Ensuring consent is a prerequisite for the ethical conduct of a trial. The execution 
of consent in this case is especially concerning because the decision made by the 
subject affected whether he was placed in inpatient medical therapy or enrolled in 
an outpatient clinical trial. Each of these two choices was described as therapeutic 
options, which can create a therapeutic misconception when reviewing the clinical 
trial. In combination with the mental instability of the participant, this decision 
has potential to not be evaluated reasonably (Shamoo & Irving, 1993). The 
inclusion of a surrogate in this process could have been beneficial in determining 
whether to continue medical treatment or to enroll in the trial.  
 As the trial continued, the mother noted changes in the behavior of the 
subject and attempted to reach out to the investigators. Based on her impression of 
her son, she described a decrease in mental capacity, similar to that of his initial 
admission to the hospital, and thought that trial was not therapeutically beneficial 
anymore. The investigators rejected her requests for the discontinuation of the 
trial. The change in mental status could have affected the subject‘s awareness of 
his condition and incapable of determining whether to discontinue participation. 
This is similar to the initial decision to administer medical care because his 
condition was not stable enough to make proper decisions regarding his health 
and overall well-being. By not recognizing a shift in the participant‘s condition, 
the study and subject is put at risk in relation to the state of autonomy. Each 
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subject will not express the same mental condition and the uniform protocol 
should not be used overshadow discrepancy in respect toward the subjects.  
 
ii. Physician Insight 
 Physician-patient relationships are highly influential in patient care. 
Although the physician plays an important role in treatment, the patient is also 
responsible for open communication and autonomous decision making. It is the 
physician‘s duty to create a space for the patient to actively participate in this 
manner. With the establishment of the patient‘s rationality and intentions of 
treatment, the physician could be to realize if the patient capacity to act in this 
role changes or diminishes in any way. Decreased mental capacity should be seen 
as a danger to decision-making and medical treatment. The autonomy of the 
patient as well as the health status of the patient is compromised. At this point, the 
welfare of the patient should be put first and treatment should be reevaluated. 
 The case of the drug trial shows a decline in mental capacity but no 
change in the patient‘s decision making responsibilities. The patient continues to 
give their status and thoughts of the treatment course to the investigators, via the 
social worker. At this point, the patient may not be able to engage in the 
physician-patient relationship as previously done and may not be able to ask 
proper questions or state concerns about the treatment which would affect the 
course of treatment. In terms of patients with inability to make competent 
decisions, a legal proxy is to act on their behalf in the physician-patient 
relationship. This is highlighted by the AMA for instances of clinical research, 
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noting increased vulnerability with participation. The physician is to engage with 
the proxy so that they can make a decision on behalf of the patient. In this case, 
the mother of the participant (or another proxy) could have discussed the 
continuation of the trial with the physician and determined an appropriate course 
of treatment from that point forward. The trial may have been still chosen as that 
method of treatment, but the vulnerable mental state of the patient would have 
been better served.  
 
2. Research as Medical Treatment - Coercion and Misconception 
i. Concern 
 Upon enrollment in the trial, the patient/participant was presented with 
two options. These options consisted of continuing in-patient medical care or 
participating in the drug trial with out-patient follow up. Medical practice and the 
conduct of research have distinct goals. Medical practice involves the actions with 
therapeutic intent and expectation for success whereas research has the goal of 
advancing current knowledge of the field (The Belmont Report, 1991). The 
knowledge gathered from clinic trials can lead to successful therapy, however it is 
not the immediate goal or expectation of participation in the trial. Although these 
two choices can be ethically sound standing alone, trouble can arise when pinning 
them against each other. It creates the perception that each option has equivalent 
therapeutic benefit, a misconception that should be controlled in order for proper 
consent to be given. This can be seen as coercion for enrollment and is not 
ethically justifiable. 
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 The terms of enrollment can also seen as a potential for coercion. The 
settings of the two options differed greatly. Medical treatment would cause the 
participant to be essentially institutionalized, where the trial allowed the patient to 
continue living out of the hospital, in a half-way house. The perks of a more 
independent atmosphere can be seen as a draw toward the option of enrollment. In 
combination with the participants uncertain mental status, these differences can be 
magnified and unjustifiably influence the participants decision to enroll. 
 Also, medical practice and research fall under two distinct bodies of 
legislation. In medical practice, the physician engages in a contractual relationship 
with their patient. The physician acts to increase the well-being of the patient 
based on their medical complaint at the formation of the relationship. Harm 
caused from improper informed consent to deviating from the standard of care can 
be grounds for neglect, a legal responsibility of the physician. This reflects the 
goal of medicine to take actions to increase the health of the individual. The 
physician is responsible for using medical knowledge and therapy diligently to 
promote therapeutic outcomes.  
 Research, on the other hand, is regulated differently. When consenting to 
research, foreseeable harms are accepted as a part of participation. It is up to the 
participant, and sometimes the investigator, to decide whether or not to stay 
enrolled in the trial based on changes in well-being. The investigator may even 
provide a set compensation or medical care in some cases of harm, but it is not a 
requirement. Overall, the investigator is not held personally responsible for health 
outcomes of the participant, even if he/she is also a physician. Without 
   39 
understanding the differences in between practice and research, the participant 
may not understand the responsibility of the CI in cases of harm or unsuccessful 
attempts at therapy. This could affect their decision on whether to choose the 
clinical trial over the medical treatment, or vice versa.  
 
ii. Physician Insight 
 It is stated in the AMA‘s Code of Ethics that physicians participating in 
research are not to act in ways that may coerce the participant to enroll in clinical 
trials, including through exaggeration of the benefits or any false understanding of 
the purpose of the trial. By acting in this way, the welfare of the patient can be 
compromised, which goes against the principles of medical practice and decreases 
trust within the physician-patient relationship. Clinical research as treatment is not 
unethical in itself, but it requires physicians to manage addition conflicts of 
interest and potential for misconceptions by the patient.  
 Physicians are required to provide patients with options for treatment on a 
daily basis. They present the risks and benefits of different therapies and can 
guide the patient to the making a choice on their treatment plan. Maintaining 
autonomy during this process is crucial to protecting the well-being of the patient. 
Adding the option of a clinical trial for treatment creates another layer of 
complexity in avoiding undue influence on their decision. The AMA suggested 
that informed consent for the trial should be done apart from the physician-patient 
relationship, so the goals of research have a lower chance to get misconstrued. 
But, as stated by the APA, it is the provider‘s duty to maintain fidelity and 
   40 
responsibility in managing any conflicts of interest, like those arising from the 
duality of medicine and research. 
 Beyond the complexity of presenting research as a treatment option, 
physicians must maintain that they are treating a human during the course of 
treatment, not the disease, as set out in the Hippocratic Oath. Similarly, the patient 
is an individual, not the product of research subject qualifications. The discussion 
and recommendation of treatment options, including research, should reflect the 
needs of the individual and their well-being, not the interests of the research trial‘s 
need for participation. In this case, the terms of the treatment options may have 
swayed the patient‘s decision. Especially knowing the fragility of the patient‘s 
mental status, physicians may have approached the decision making process 
differently in order to improve the patient‘s ability to make an autonomous and 
health-focused choice. 
 
3. Research as Medical Treatment - Quality of Care 
i. Concern 
 Continuing with the blurred perception of research and treatment, the 
consent in deciding between in-patient medical care and out-patient trial 
participation should clearly distinguish differences in medical follow up. The 
mother of the subject reports that follow up was rarely completed by a physician 
or psychologist. Instead, the participant was visited by a social worker. Although 
the social worker can discuss with the patient and conduct any survey provided by 
the trial, they do not provide the same kind of care as a physician, psychiatrist or 
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psychologist. With these visits occurring with days in between, quick changes in 
mental status may not be recognized at their onset and result in harms that could 
have been avoidable.  
 This choice of follow up in itself is not ethically unjustifiable, but when 
the trial is placed as an option against the in-patient medical care, discrepancy in 
quality of follow up is assumed to be sizable. Stemming from the use of this 
research trial as a treatment option, the follow up by the social worker greatly 
differs from the monitoring of in-patient medical care. Although the amount of 
time given in the follow up may be the same in each location, the accessibility to 
care upon changes in mental status is significantly greater when in the hospital. 
Also, the administration of the drug is monitored by medical personnel when in 
the hospital. The understanding of these differences may make a difference when 
determining whether or not to participate in the trial. Overall, the expectation of 
medical follow up for the option chosen should be recognized and understood, 
which may have been blurred in this example with non-institutionalization being 
offered to the patient. 
 Although it is not a requirement of investigators in research, the fact that 
the participant was not removed from the trial when therapeutic benefit was not 
achieved, actually showing a decline in mental status, is unsettling. In the 
subject‘s initial 14-day medical hold, the patient was placed on a drug regimen of 
Risperdal and did not show a similar decline. In fact, after the course of the drug, 
the subject was deemed as capable to make rational decisions regarding his 
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health, an improvement from his initial state of incapacity. This choice of 
treatment was seen as successful in this time frame.  
 Risperdal was one of the drugs under comparison, but the blind nature of 
the study hid the identity of the drug given to the subject. Therefore, the subject 
had potential to continue with the course of the medical, which had proven 
beneficial to the point of enrollment. However, the patient was placed on another 
drug, Seroquel, and did not have a favorable response. With the decline in the 
health of the subject, it is concerning that the investigator did not discontinue the 
course of the experimental drug (also unknown to the investigator) and restart the 
course of Risperdal. The harm caused to the subjects was foreseeable and 
avoidable, but the study continued. Although the drugs used in the modern case 
are FDA-approved, it cannot be expected that they will work effectively for each 
patient. And, if a standard of therapy exists for that patient, it should be 
implemented in the case of health decline when using a blind drug trial.  
 Although this should apply in cases of varying severities of health 
conditions, the ramifications of symptom onset in this case creates harm for both 
the patient as well as others around them. The subjects that were enrolled in the 
study presented with homicidal ideation, meaning they stated plans of killing 
others when experiencing a change in mental status. When showing a decline in 
mental status, the subject should have been removed from the trial, decreasing the 
potential for harm in this manner. This decline did lead to the suicide of the 
subject, an outcome that may have been avoided when a known successful 
therapy existed. 
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ii. Physician Insight 
 Physicians not only have an obligation to give respect and dignity to the 
patient, but to be responsive and provide care in a timely manner based on the 
physician patient relationship, as described by the AMA. In this case, the 
arrangement for follow up by the Social Worker may have caused 
miscommunication in the care regimen for multiple reasons. Despite the cause of 
this gap in information, the patient was not cared for in a responsive way or a 
timely manner. It can be inferred that the lack of response to the patient‘s decline 
is what lead to the outcome seen in the case. Therefore, with insight of a 
physician along with proper communication between those involved in the 
administration of the trial, the failure of the experimental drug could have been 
recognized earlier and a return to the initial treatment could have improved health 
outcomes. 
 If the researchers had used the ethical standards of clinical care rather than 
research, individual outcomes might have been significantly improved. As stated 
in the Hippocratic Oath, physicians are to prescribe treatment regimens to the best 
of their skill and to not cause harm to the patient. The physicians involved in the 
case had the known ability to treat the participant‘s condition and not cause harm, 
as seen in the holding period prior to the decision to starting the trial, but did not 
act on this knowledge when the trial drug did not improve the health status of the 
patient. The physician is to practice medicine to the best of their knowledge and 
judgment, which may have lead to a change in treatment - the removal from the 
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trial. As stated in the AMA‘s Code of Ethics, it is principle that physicians should 
put the welfare of patients first. The patient‘s health comes before expectations of 
institutions, personal endeavors, and clinical research itself. And, above all, the 
patient‘s well-being trumps progress of the clinical trial. In this case, the patient‘s 
welfare appeared to be compromised from the decline of the patient‘s health 
during the drug trial. The role of the physician would address this concern before 
handling the remainder of the trial or any personal dedication to the project. By 
focusing on the health of the patient, the potential for harm may have decreased. 
 




1. Tilting Scales: Ethos & Regula 
 As seen in the history of clinical research, legal regulation of research has 
taken on a role of translating clinical research ethics standards into governance of 
the execution of drug trials. The effectiveness and weight of current regulation in 
human subject research must be reconsidered. The structure of the trial in the case 
study presented with, what appears to be, great odds for success in the balance of 
the protection of human subjects and quality scientific results. This research was 
being completed at a well-known research institution within the academic setting. 
The academic setting provides access to experts in the field, education of both 
medicine and science, resources necessary for the completion of research, a well-
developed health system, and the protection of a regulated institutional review 
board, to name a few. But, despite the abundance and quality of these resources, 
the current regulatory format still failed to illuminate problems in the research 
endeavor that compromised the beneficence, the respect for subjects, and justice 
of the trial.  
 The case presented here seems to fall into the same trend seen in the 
history of research regulation. People are harmed when participating in a research 
trial, resulting in a negative public response to clinical research. This was seen in 
the cases of the Nazi War Crimes, the cases discussed in Beecher‘s publication, 
and the Tuskegee Syphilis Trials. Historically, the next step in cases of this nature 
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was the ordering of reform to the regulation. So, if this trend would continue, the 
flaws seen in this modern drug trial would catalyze the addition of more legal 
requirements on research to account for the new challenges presented. But, more 
than anything, this trend should demonstrate that regulation is not successful and 
lagging behind many issues in modern clinical research. If flaws in research are 
happening within this high tier of scientific research and they are not revealed 
until the investigation of the death of a participant occurs, it calls into question 
what other lapses in participant protection are overlooked within the current 
regulatory structure of clinical research. 
 With the failure of regula to providing sufficient protection of human 
research subjects, a shift back toward the prominence of ethos in research and 
practice may be the next best option. However, it is difficult to imagine 
completely reverting to the structure of ethos with the dramatic changes 
regulation has played in the structure of clinical research. Problems seen in the 
execution of medical research governed by ethos catalyzed both national and 
international regulation. The protection of human subjects in research was not 
shown to be successful under the discretion of physicians and scientific 
investigators alone. Especially with challenges of conflict of interest present 
among pharmaceutical research today, placing trust in the individual to manage 
this tension without bias could get messy and cause even more exploitation of 
participants. 
 A strategic balance among ethos and regula must be achieved in order to 
best protect participants of clinical research. The strengths and intentions of each 
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have shown to weaken in instances where one took precedence over the other. 
Although law and ethics have the ability to contradict, the use and practice of both 
ethos and regula is dependent on the other. The success of this relationship is 
contingent on correct perceptions of both regulation and ethics standards by the 
CI in correlation to the execution of research. This case‘s concerns and analysis 
illuminate relevant misunderstandings of regula and ethos, which can negatively 
affect participant protection. Understanding these misconceptions can provide 
insight to the future development of regulation and ethical standard as well as the 
practice of medicine and clinical research. 
 
2. Misconceptions of Regula - IRB Approval 
 The IRB is in charge of accepting or denying a research trial for 
continuation with the use of human subjects. This process includes portions that 
focus on the protection of subjects, including statements of participation selection, 
informed consent, and expected risks and benefits of the trial. Once approved, the 
trial is able to proceed with the accepted protocol. In a recent survey by Fisher, 
physicians had the understanding that the trial was ethically sound when 
becoming a CI for an approved trial (2008). This shows that a blind trust may 
exist in the current regulatory system of clinical research to determine what is 
considered ethically-justified. The reliance on the IRB in this way could be 
contributing to the questionable treatment of research participants.  
 Safeguards placed throughout the protocol application can be designed to 
help to control compromising scenarios, but this may not translate properly when 
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the trial is active. The investigator should be able to identify the ethical issues of 
the trial and take action to protect each individual subject. This is especially 
important when executing informed consent. Although the proper information 
about the trial and the documentation has been approved by the IRB, not all 
participants may be able to comprehend the information at the same level. The 
aforementioned trial acts as a relevant example of this due to the variation in 
mental statuses of the participants involved. Each participant could require 
individualized attention to best ensure the protection of their autonomy as well as 
throughout the course of the protocol, which is a responsibility of the investigator.  
 As described by Fisher, some physicians executing research protocols 
believed that the management of ethics was not a personal responsibility since the 
trial had been approved by an institutional review board (2008). The fact that the 
IRB proposal for the trial addresses the ethical challenges presented it in the case 
and is approved does not relinquish the responsibility to monitor for these 
challenges during the course of the subject‘s participation. Ethics must be 
addressed continuously while the trial is occurring and is a primary responsibility 
of the investigator, despite their level of involvement in the trial development. 
CI‘s should expect to take an active role in the ‗practice‘ of clinical research 
ethics instead of relying on regula to ensure participant protection. Overall, the 
skewed perception of regula in human subject research may be unintentionally 
restraining investigators from accountability for the protection of subjects during 
the trial. 
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3. Misconceptions of Ethos – Clinician Investigators and Duality 
 The conflict of the duties of the physician and scientific investigator 
within the role of a Clinician Investigator tends to cloud the discussion of CI 
research ethics. Specifically, the balance of these two sets of ethos has yet to be 
achieved. This is concerning seeing that both physicians and researchers have 
sound standards of ethics that are widely accepted. Currently, ethical standards 
have suggested that physicians work to separate their designation as a medical 
provider to avoid misconception on the part of the research subject. Although it 
makes sense for the physician distinguish the goals of research from therapy when 
acting as a CI, having the physician assume the ethos of the scientific investigator 
and abandon physician ethos may not present the best opportunity for patient 
protection. The misconception of ethos within the ‗resolutions‘ of this duality can 
pose a hurdle to participant protection. 
 Patient welfare stands at the forefront of both medical practice goals and 
ethos for the physician. Though the purpose of research may be to promote the 
advancement of scientific knowledge, an aspect to research ethics is protecting the 
welfare of the participant, although not therapeutic in nature. In this similarity, the 
rise of the Clinician Investigator may shift from a challenge to an advantage in the 
personal development and execution of ethos. With practice in medicine grounded 
it values encompassing patient protection and personal responsibility in the 
physician-patient relationship, participants may be more suitable hands of an 
investigator with the ethical experience of a physician.  
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 Using the patient care experience of the physician during research does 
not necessarily lead to the goals and protocol of the trial being compromised. 
Research will continue to serve the purpose to increase the knowledge of the field, 
not to provide medical therapy. The physician‘s relationship with the patient does 
not suggest they will promote treatment over research, but that they will be able to 
identify the best suited participants for the trial. The institutions and companies 
involved in the development of drugs and medical devices will still stand at the 
forefront of the creation of protocols and their execution. Trials will follow 
protocol, with exceptions being for declines in health. Removal of subjects with 
declining health should not compromise the trials, for the serious side effects will 
demonstrate ineffectiveness of the drug as well as a fatality. It could even help the 
research institutions and companies avoid legal action resulting from cases of 
avoidable harm. Any change to increase the follow up of patients will only 
provide the trial with more data. Also, the participation of the physicians could 
help to disperse any information gathered in the trial to the health environments 
which they already exist.  
 The experience of physicians could enhance the informed consent process 
in creating an open environment for questions and discussion. The familiarity of 
relationships with physicians could enhance the initial trust in the trial. The 
participant may be more comfortable to ask questions in order to come to an 
autonomous decision. The physician‘s knowledge of health could provide 
additional questions participants have about the risks and benefits of the trial. 
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Medical experience could give participants an additional sense of security in the 
case that side effects do occur and medical attention is needed. 
 The patient‘s well-being throughout the course of the trial can also be 
enhanced by the physician‘s ethos in clinical research. The qualities of 
responsiveness and timeliness of care will improve the protection of patient‘s in 
cases of harm and declining health. The participants in need of additional care 
outside of the trial will be recognized and transfer of care will be addressed. The 
continued focus on the participants will help to manage any conflicts of interest, 
including obligations to the institutions and personal goals. Treating participants 
with the care of patients will help to promote their well-being throughout the 
research process and improve participant protection. Although it may appear to 
solve problems in therapeutic misconception by creating a division between the 
roles of research investigator and physician, abandoning patient-centered values 
to execute trial protocol may compromise the welfare of subject. The CI may be 
able to better protect subjects through maintaining their values from medical 
practice while acting as research investigator. 
 




 As seen in the reviewed case study, even the most potentially strong 
foundations for ethically standardized and closely regulated research are quaking 
at the onset of new challenge in contemporary research trends. More scrutiny 
must be made of both the legal regulation and ethical governance of clinical 
research as for-profit pharmaceutical research moves beyond the academic setting 
and into private practice, away from the applauded oversight of academic 
institutions.  
Through better understanding the purpose of regulation and ethical 
standard in relation to the personal responsibilities of the CI, increased subject 
protection can be present in the development, approval and execution of clinical 
trials. Misconceptions of both the regulation of clinical research and the moral 
norms of physicians and researchers will continuously need to be managed in 
order to promote personal responsibility of the CI to be involved in the ethics of 
the trial. But, through bridging the discrepancies in both regulation and ethics, 
movement can be made toward protecting the well-being of subjects while 
leaving room for scientific innovation to continue in both the academic and 
private sector settings. 
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